Statistics

Total Visits

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)86

Select a period of time:

Number of views in the range

Views
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)32

Views

Views
July 202521
August 20250
September 20250
October 20252
November 20257
December 20252
January 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States10
Brazil9
United Kingdom3
Turkey2
Colombia2
Canada1
Chile1
Ecuador1
Honduras1
Uruguay1
 

Top cities views

Views
Istanbul2
Ashburn2
Alvorada do Norte1
Ananindeua1
Belo Horizonte1
Clovis1
Compton1
Everett1
Guarulhos1
Manchester1